During the first period (M1–M15), the IFIGENEIA consortium successfully established the scientific, technical, organisational and exploitation foundations required to achieve the project's long-term objectives. The project progressed according to the Grant Agreement, with all planned activities initiated and the scheduled deliverables submitted on time.
The project governance structure became fully operational through the establishment of the Management Board, Project Steering Committee, General Assembly and External Advisory Board, ensuring effective coordination of the 22 partners from six countries. Robust project management, quality assurance, risk management, ethics, intellectual property and FAIR-compliant data management frameworks were implemented, providing a solid basis for efficient project execution.
Significant scientific progress was achieved towards the development of the future LINAC-based infrastructure for medical radioisotope production. Accelerator design activities advanced through RFQ design studies, beam dynamics simulations and manufacturing planning, while a common methodology linking clinical requirements, radionuclide production, target optimisation and accelerator specifications was established. Following joint assessments by WP3 and WP4, Lu-177 was selected as the baseline radioisotope for the initial accelerator design and business planning activities.
In parallel, the radiopharmaceutical development framework was established through the definition of GMP laboratory specifications, radionuclide prioritisation, identification of clinically relevant molecular targets and preparation for future preclinical studies. Close collaboration between the technical and clinical work packages ensured the alignment of accelerator development with future healthcare applications.
The project also made substantial progress in communication, dissemination, education and stakeholder engagement. The project website, visual identity, communication channels and dissemination materials were successfully deployed, while mentoring activities, Particle Therapy Master Classes and capacity-building actions strengthened collaboration among partners and supported the integration of widening countries, including the preparation of the Bosnia and Herzegovina Excellence Hub.
Finally, exploitation and sustainability activities were initiated through the identification of seven Key Exploitable Results, market and business analyses centred on Lu-177 production, and preparatory work for the Strategic Investment Plan and future Business Plans. These activities established the foundations for the long-term sustainability, exploitation and societal impact of the IFIGENEIA Excellence Hubs.